Analysts Set Enfusion, Inc. (NYSE:ENFN) Price Target at $10.50

Enfusion, Inc. (NYSE:ENFN - Get Free Report) has earned an average recommendation of "Hold" from the six research firms that are currently covering the company, Marketbeat.com reports. Two equities research analysts have rated the stock with a sell recommendation, two have given a hold recommendation and two have issued a buy recommendation on the company. The average twelve-month price objective among analysts that have updated their coverage on the stock in the last year is $10.50.

A number of analysts have recently issued reports on the stock. Stifel Nicolaus boosted their target price on shares of Enfusion from $11.00 to $13.00 and gave the company a "buy" rating in a research note on Wednesday, December 18th. William Blair reissued a "market perform" rating on shares of Enfusion in a research report on Monday, January 13th. Finally, Piper Sandler raised their target price on shares of Enfusion from $10.00 to $11.50 and gave the stock a "neutral" rating in a research report on Monday, December 23rd.

Insider Buying and Selling

In other news, CFO Bradley Herring sold 24,443 shares of the company's stock in a transaction that occurred on Friday, December 20th. The shares were sold at an average price of $10.61, for a total value of $259,340.23. Following the completion of the sale, the chief financial officer now owns 270,503 shares of the company's stock, valued at approximately $2,870,036.83. This represents a 8.29 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, COO Neal Pawar sold 21,801 shares of the stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $10.03, for a total transaction of $218,664.03. Following the transaction, the chief operating officer now owns 1,143,544 shares in the company, valued at approximately $11,469,746.32. This represents a 1.87 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 57,367 shares of company stock valued at $591,335 over the last three months. 36.44% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. TenCore Partners LP bought a new stake in Enfusion during the third quarter valued at about $3,938,000. New York State Common Retirement Fund boosted its holdings in shares of Enfusion by 23.8% in the 4th quarter. New York State Common Retirement Fund now owns 1,926,968 shares of the company's stock valued at $19,848,000 after buying an additional 370,498 shares in the last quarter. Impax Asset Management Group plc grew its position in shares of Enfusion by 31.5% in the 4th quarter. Impax Asset Management Group plc now owns 890,000 shares of the company's stock worth $9,167,000 after buying an additional 213,052 shares during the last quarter. Dimensional Fund Advisors LP grew its position in shares of Enfusion by 57.5% in the 2nd quarter. Dimensional Fund Advisors LP now owns 524,142 shares of the company's stock worth $4,466,000 after buying an additional 191,436 shares during the last quarter. Finally, JPMorgan Chase & Co. raised its stake in shares of Enfusion by 612.4% during the 3rd quarter. JPMorgan Chase & Co. now owns 208,022 shares of the company's stock worth $1,974,000 after acquiring an additional 178,821 shares in the last quarter. 81.05% of the stock is owned by institutional investors.

Enfusion Price Performance

Shares of ENFN traded down $0.06 during mid-day trading on Thursday, reaching $11.17. 1,184,680 shares of the company's stock traded hands, compared to its average volume of 1,352,900. The stock's 50-day moving average is $10.66 and its two-hundred day moving average is $9.52. Enfusion has a 12 month low of $7.83 and a 12 month high of $11.38. The stock has a market cap of $1.44 billion, a P/E ratio of 279.19, a P/E/G ratio of 1.83 and a beta of 0.96.

Enfusion Company Profile

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.